NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July
NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July
CAMBRIDGE, Mass., July 11, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a company overview at the Emerging Growth Conference on Thursday, July 18, 2024 at 10:50 am ET.
生物技術公司NeuroBo Pharmaceuticals，Inc. (納斯達克：NRBO)2024年7月18日上午10:50 (美國東部時間)將於新興成長會議上舉行公司概況的演講。公司總裁兼首席執行官金亨賢和首席財務官Marshall H. Woodworth將出席並進行公司概述。
During the virtual presentation, management will provide an update on the clinical development of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity.
此次網絡演講中，管理層將更新DA-1726的臨床研究進展。DA-1726是一種新型雙氧合酶調製劑(OXM)類似物的拮抗劑，具有促進胰高血糖素樣肽-1受體(GLP1R)和胰高血糖素受體(GCGR)的雙重作用，用於肥胖症的治療。
After the presentation, NeuroBo management will open the floor for questions. Please submit your questions in advance to [email protected], or ask your questions during the event.
演示結束後，NeuroBo管理團隊將接受提問，歡迎提前將您的問題發送至[email protected]，或在活動期間現場提問。
Please register using this link to attend the virtual conference and receive any updates that are released. To schedule a meeting with management outside of the conference, please contact Michael Miller at [email protected].
請通過此鏈接註冊參加虛擬會議並接收任何發佈的更新信息。如果想在會議之外安排與管理團隊的會議，請通過[email protected]聯繫Michael Miller。
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control.
關於NeuroBo Pharmaceuticals
NeuroBo製藥公司是一家處於臨床階段的生物技術公司，專注於改善心血管代謝性疾病。該公司目前正在開發DA-1726治療肥胖症，並正在開發DA-1241治療代謝失調相關的脂肪肝病（MASH）。DA-1726是一種新型氧合肽素（OXM）類似物，它作爲胰高血糖素樣肽-1受體（GLP1R）和胰高血糖素受體（GCGR）的雙重激動劑。氧合肽素是一種自然出現的腸道激素，可以激活GLP1R和GCGR，從而減少食物攝入，增加能量消耗，因此可能比選擇性GLP1R激動劑產生更好的體重減輕效果。DA-1241是一種新型G蛋白偶聯受體119（GPR119）激動劑，可以促進關鍵腸道肽GLP-1，GIP和PYY的釋放。在臨床前研究中，DA-1241表現出對肝臟炎症、脂代謝、體重減輕和葡萄糖代謝的積極影響，減少肝臟脂肪變性、肝炎症和肝纖維化，同時改善葡萄糖控制。
For more information, please visit .
有關更多信息，請訪問。
Contacts:
聯繫人：
NeuroBo Pharmaceuticals
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
[email protected]
NeuroBo Pharmaceuticals
Marshall H. Woodworth
致富金融(臨時代碼)
+1-857-299-1033
[email protected]
Rx Communications Group
Michael Miller
+1-917-633-6086
[email protected]
Rx Communications Group
Michael Miller
+1-917-633-6086
[email protected]
SOURCE NeuroBo Pharmaceuticals, Inc.
來源：NeuroBo Pharmaceuticals，Inc。